ACSS1

Across TCGA pan-cancer cohorts, ACSS1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACSS1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACSS1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACSS1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ACSS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.905	0.668	.004	20	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.766	.013	8	view →
LUAD	DFS	Median	All	1.000	0.898	.021	7	view →
HNSC	DFS	Median	III,IV	0.876	0.707	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACSS1–PDAC (DFS)

Open the PDAC breakdown →